Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter

Prostate

Volumn 59, Issue 4, 2004, Pages 370-382

  Yu, Duan ^a   Jia, William W ^a   Gleave, Martin E ^a   Nelson, Colleen C ^a   Rennie, Paul S ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Androgen regulation; Prostate cancer; Retrovirus; Tissue specific promoter

Indexed keywords

ANDROGEN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; PROBASIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CHROMATIN; CONTROLLED STUDY; EMBRYO; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RETROVIRUS;

ANDROGEN-BINDING PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LENTIVIRUS; LUMINESCENT PROTEINS; MALE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 2442716353     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20010     Document Type: Article

References (43)

1. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000;88(12 Suppl):3009-3014.
2. Long RJ, Roberts KP, Wilson MJ, Ercole CJ, Pryor JL. Prostate cancer: A clinical and basic science review. J Androl 1997; 18(1):15-20.
3. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994;91(23):11236-11240.
4. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000;19(8):1020-1027.
5. Cleutjens KBJM, Van der Korput HAGM, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman JA. 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endcrinol 1997; 11(9):1256-1265.
6. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000;60(2):334-341.
7. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, Zandvliet D, Russell PJ, Molloy PL, Nowak NJ, Shows TB, Mullins C, Vonder Haar RA, Fair WR, Heston WD. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998;1443(1-2):113-127.
8. Good D, Schwarzenberger P, Eastham JA, Rhoads RE, Hunt JD, Collins M, Batzer M, Theodossiou C, Kolls JK, Grimes SR. Cloning and characterization of the prostate-specific membrane antigen promoter. J Cell Biochem 1999;74(3):395-405.
9. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckwort ML, Rosen JM, Matusik RJ. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8(2):230-239.
10. Yan Y, Sheppard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML, Matusik RJ. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 1997;32(2):129-139.
11. James GK, Pudek M, Berean KW, Diamandis EP, Archibald BL. Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol 1996;106(2):242-247.
12. Lintula S, Stenman UH. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 1997;157(5):1969-1972.
13. Diamandis EP. Prostate specific antigen-New applications in breast and other cancers. Anticancer Res 1996;16(6C):3983-3984.
14. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 1997; 94(12):6369-6374.
15. Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998;60(1):220-229.
16. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA, Matusik RJ. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993;7(1):23-36.
17. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L, Shiu RP, Snoek R, Matusik RJ. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 1994; 269(50):31763-31769.
18. Reid KJ, Hendy SC, Saito J, Sorensen P, Nelson CC. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J Biol Chem 2001;276(4):2943-2952.
19. Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Differential transactivation by the androgen receptor in prostate cancer cells. Prostate 1998;36(4):256-263.
20. Yeung LH, Read JT, Sorenson P, Nelson CC, Gleave M, Jia W, Rennie PS. Identification and characterization of a prostate-specific androgen independent protein binding site in the probasin promoter. Biochem J 2003;371(Pt 3):843-855.
21. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141(12):4698-4710.
22. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001; 93(17):1314-1324.
23. Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, Spencer DM. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001;61(18):6795-6804.
24. Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther 2001;8(18):1363-1371.
25. Martiniello-Wilks R, Tsatralis T, Russell P, Brookes DE, Zandvliet D, Lockett LJ, Both GW, Molloy PL, Russell PJ. Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther 2002;9(5):443-452.
26. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998;95(19):11377-11382.
27. Pfeifer A, Verma IM. Gene therapy: Promises and problems. Annu Rev Genomics Hum Genet 2001;2:177-211.
28. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001;8(9):628-635.
29. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993;90(17):8033-8037.
30. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259):263-267.
31. Rennie PS, Bruchovsky N, Akakura K, Goldenberg SL, Otal N, Akakura S, Wong P, Tenniswood M. Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma. J Steroid Biochem Mol Biol 1994;50(1-2):31-40.
32. Brookes DE, Zandvliet D, Watt F, Russell PJ, Molloy PL. Relative activity and specificity of promoters from prostate-expressed genes. Prostate 1998;35(1):18-26.
33. Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, Snoek R, Dahlman-Wright K, Gustafsson J-A, Shiu RP, Sheppard PC, Matusik RJ. Selective activation of the probasin androgen-responsive region by steroid hormones. J Mol Endocrinol 1999;22(3):313-325.
34. Herrlinger U, Pechan PA, Jacobs AH, Woiciechowski C, Rainov NG, Fraefel C, Paulus W, Reeves SA. HSV-1 infected cell proteins influence tetracycline-regulated transgene expression. J Gene Med 2000;2(5):379-389.
35. Yang C-T, Song J, Bu X, Cong Y-S, Bacchetti S, Rennie PS, Jia W. Herpes simplex virus type-1 infection up regulates cellular promoters and telomerase activity in both tumor and non-tumor human cells. Gene Therapy 2003;10(17):494-502.
36. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992;31(8):2393-2399.
37. Huang W, Shostak Y, Tarr P, Sawyers C, Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 1999;274(36):25756-25768.
38. Evangelou A, Letarte M, Marks A, Brown TJ. Androgen modulation of adhesion and antiadhesion molecules in PC-3 prostate cancer cells expressing androgen receptor. Endocrinology 2002;143(10):3897-3904.
39. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Cleutlens K, Noordzil A, Trapman J, Visakorpi T, Kallioniemi O-R. Androgen receptor gene amplification: A possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res 1997;57(2):314-319.
40. Scherr M, Battmer K, Blomer U, Schiedlmeier B, Ganser A, Grez M, Eder M. Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood 2002;99(2):709-712.
41. Hamaguchi I, Woods NB, Panagopoulos I, Andersson E, Mikkola H, Fahlman C, Zufferey R, Carlsson L, Trono D, Karlsson S. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol 2000; 74(22):10778-10784.
42. Temme A, Morgenroth A, Schmitz M, Weigle B, Rohayem J, Lindemann D, Fussel M, Ehninger G, Rieber EP. Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34(+) cord blood-derived dendritic cells. Gene Ther 2002;9(22):1551-1560.
43. Bruchovsky N, Rennie PS, Wilkin RP. New aspects of androgen action in prostatic cells: Stromal localization of 5a-reductase, nuclear abundance of androstanolone and binding of receptor to linker deoxyribonucleic acid. In: Schroder FH, deVoogt HJ, editors. Steroid receptors, metabolism, and prostatic cancer. New York: Excerpta Medica; 1980. pp 57-76.